| 國家衛生研究院 |
2023-11 |
ILLUMINATE: Efficacy and safety of durvalumab-tremelimumab and chemotherapy in EGFR mutant NSCLC following progression on EGFR inhibitors
|
Lee, C;Liao, BC;Subramaniam, S;Chiu, CH;Mersiades, A;Ho, CC;Brown, C;Lai, CL;Hughes, BGM;Yang, TY;O'Byrne, K;Luo, YH;Yip, S;Ho, CL;Bray, V;Su, WC;Moore, M;Feng, WL;Bai, YY;Stockler, M;Solomon, B;John, T;Yang, JCH |
| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
|
Sequist L.V;Chih-Hsin Yang;Yamamoto N;O'Byrne K;Hirsh V;Mok T;Geater S.L;Orlov S;Tsai C.-M;Boyer M;Su W.-C;Bennouna J;Kato T;Gorbunova V;Lee K.H;Shah R;Massey D;Zazulina V;Shahidi M;Schuler M.; Sequist L.V; CHIH-HSIN YANG; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
|
Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. |
| 臺大學術典藏 |
2020-05-26T09:26:51Z |
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: Post hoc analyses of the randomized LUX-Lung 3 and 6 trials
|
Shah R; Märten A; Massey D; Wind S; Wu Y.-L.; Dickgreber N; Okamoto I; Sebastian M; Huang Y; Hirsh V; Lu S; O'Byrne K; Feng J; Wu Y.-L.;Wind S;Massey D;M?rten A;Shah R;Dickgreber N;Okamoto I;Sebastian M;Huang Y;Hirsh V;Lu S;O'Byrne K;Feng J;Yamamoto N;Hu C.-P;Mok T;Geater S.L;Schuler M;Zhou C;Sequist L.V;Chih-Hsin Yang; CHIH-HSIN YANG; Sequist L.V; Zhou C; Schuler M; Geater S.L; Mok T; Hu C.-P; Yamamoto N |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases
|
Chih-Hsin Yang;Zazulina V;Massey D;Sequist L.V;Popat S;Mok T;Yamamoto N;O'Byrne K;Hirsh V;Wu Y.-L;Schuler M; Schuler M; Wu Y.-L; Hirsh V; O'Byrne K; Yamamoto N; Mok T; Popat S; Sequist L.V; Massey D; Zazulina V; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:47Z |
140PD: LUX-Lung 7: A Phase IIb, global, randomised, open-label trial of afatinib vs gefitinib as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations
|
Mok T; Kim M; Paz-Ares L.; Paz-Ares L.;Kim M;Mok T;Chih-Hsin Yang;Boyer M;O'Byrne K;Hirsh V;Zhang L;Tan E.-H;Park K; Park K; Tan E.-H; Zhang L; Hirsh V; O'Byrne K; Boyer M; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:46Z |
138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
|
Wu Y.-L.;Shah R;Mok T;Hirsh V;O'Byrne K;Zhou C;Yamamoto N;Sequist L.V;Chih-Hsin Yang;Schuler M; Schuler M; CHIH-HSIN YANG; Sequist L.V; Yamamoto N; Zhou C; O'Byrne K; Hirsh V; Mok T; Shah R; Wu Y.-L. |
| 臺大學術典藏 |
2020-05-26T09:26:45Z |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial
|
Paz-Ares L.;Zazulina V;Massey D;Kim M;Shahidi M;Tsai C.-M;Laurie S.A;K?lbeck K;Arvis C.D;Kim D.-W;Laskin J;Kim S.-W;Shi Y;Lu S;Lee K.H;Chih-Hsin Yang;Hirsh V;Mok T;Boyer M;Zhang L;O'Byrne K;Tan E.-H;Park K; Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:42Z |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial
|
Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K.; Park K.;M?rten A;Dodd N;Fan J;K?lbeck K;Laurie S.A;Kim D.-W;Laskin J;Lee D.H;Shi Y;Lu S;Lee K.H;Mok T;Chih-Hsin Yang;Boyer M;Hirsh V;Zhang L;O'Byrne K;Tan E.-H;Paz-Ares L; Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG |
